252 related articles for article (PubMed ID: 23168844)
21. Is the lower cyclosporine concentration at 2 hours after dosing safe in kidney transplant recipients?
Einollahi B; Rostami Z; Kalantar E; Lessan-Pezeshki M; Pourfarziani V; Nemati E
Transplant Proc; 2011 Mar; 43(2):488-90. PubMed ID: 21440741
[TBL] [Abstract][Full Text] [Related]
22. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
23. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
24. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period?
Mahalati K; Lawen J; Kiberd B; Belitsky P
J Urol; 2000 Jan; 163(1):37-41. PubMed ID: 10604309
[TBL] [Abstract][Full Text] [Related]
25. [A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
Halacová M; Jedlicková B; Průsa R
Ceska Slov Farm; 2003 Nov; 52(6):267-71. PubMed ID: 14661365
[TBL] [Abstract][Full Text] [Related]
26. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
[TBL] [Abstract][Full Text] [Related]
27. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R
Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
29. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
[TBL] [Abstract][Full Text] [Related]
30. Limitations of C2 monitoring in renal transplant recipients.
Einecke G; Schütz M; Mai I; Fritsche L; Giessing M; Glander P; Neumayer HH; Budde K
Nephrol Dial Transplant; 2005 Jul; 20(7):1463-70. PubMed ID: 15840681
[TBL] [Abstract][Full Text] [Related]
31. Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation.
Praditpornsilpa K; Avihingsanon Y; Nivatvong S; Kansanabuch T; Eiam-Ong S; Tiranathanagul K; Chusil S; Tungsanga K
Clin Transplant; 2005 Jun; 19(3):335-9. PubMed ID: 15877794
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of cyclosporine C2 levels in long-term stable renal allograft recipients.
Hu RH; Tsai MK; Lee PH
Transplant Proc; 2004 Sep; 36(7):2105-7. PubMed ID: 15518762
[TBL] [Abstract][Full Text] [Related]
33. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
Kyllönen LE; Salmela KT
Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
[TBL] [Abstract][Full Text] [Related]
34. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporine versus tacrolimus maintenance therapy in renal transplant.
Alghamdi S; Nabi Z; Skolnik E; Alkorbi L; Albaqumi M
Exp Clin Transplant; 2011 Jun; 9(3):170-4. PubMed ID: 21649564
[TBL] [Abstract][Full Text] [Related]
36. Experience with cyclosporine: approaching the therapeutic window for C2 levels in maintenance kidney transplant recipients.
Di Paolo S; Teutonico A; Infante B; Stallone G; Schena A; Grandaliano G; Battaglia M; Di Tonno P; Schena FP
Transplant Proc; 2004 Mar; 36(2 Suppl):434S-436S. PubMed ID: 15041381
[TBL] [Abstract][Full Text] [Related]
37. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
38. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
Konstadinidou I; Boletis JN
Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
[TBL] [Abstract][Full Text] [Related]
39. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients.
Câmara NO; Dias MF; Pacheco-Silva A
Clin Transplant; 2004 Aug; 18(4):450-5. PubMed ID: 15233825
[TBL] [Abstract][Full Text] [Related]
40. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
